Consumer Groups Oppose Califf To Head FDA, Citing Industry Ties
This article was originally published in The Gray Sheet
Executive Summary
Groups including Public Citizen say the Senate should reject the president's nomination of clinical trials expert and cardiologist Robert Califf as FDA commissioner due to his prior financial ties to industry. "The Gray Sheet" takes a look at his financial conflict of interest forms from former employer Duke University, which show relationships with a range of manufacturers – although more are from the pharmaceutical arena than the medical device space. But entries in Duke University’s conflict-of-interest disclosures don't always match up to those in the government's Open Payments database.
You may also be interested in...
Sens. Manchin, Markey Join Opposition To Califf, But Obama Affirms Support
Two more senators, Edward Markey, D-Mass., and Joe Manchin, D-W.Va., announced their opposition to Robert Califf to head the FDA, citing the appointee’s financial ties to industry and weak position on prescription opioid addiction, but the White House said the president stands behind his nominee.
Califf Expected To Ace Senate Panel Vote, As He Ups Emphasis On Safety Surveillance
The Senate Health, Education, Labor and Pensions Committee plans a confirmation vote on Robert Califf Jan. 12 to become the next FDA commissioner. Public health researchers and Sens. Sanders and Warren have argued that the long-time academic research leader's ties to industry are too close. Meanwhile, Califf recently has emphasized his focus on strengthening postmarket safety oversight.
Califf Supports Combo Products Pathway At Confirmation Hearing
FDA's concepts for a new pathway could be ready for congressional scrutiny within a year, Deputy Commission Robert Califf said during his confirmation hearing before the Senate HELP Committee. Most committee members expressed support for Califf's nomination to lead FDA, although he fielded some questions on his ties to industry.